iShares Nasdaq Biotechnology Index Fund ETF News

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

Watching certain instruments for clues on next moves, probably the best (equities) to watch is the Economic Modern Family of stock market ETFs. These ETFs cover everything from tech to regional bank s

A smart beta exchange traded fund, the iShares Biotechnology ETF (IBB) debuted on 02/05/2001, and offers broad exposure to the Health Care ETFs category of the market.

The popular iShares Biotechnology ETF NASDAQ: IBB has formed a bullish consolidation in the upper portion of its 52-week range, hinting at a significant sector-wide breakout.

Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.

What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.

These top-ranked ETFs underperformed the S&P 500 in Q1 of 2024. However, these ETFs have strong potential to rebound in the coming days.

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market i

Launched on 02/05/2001, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Biotech segment of the equity market.

IBB tracks the performance of the rapidly advancing biotechnological sector. The need for advanced medical innovations is urgent to challenge serious ailments. The fund could benefit investors with up

The iShares Biotechnology ETF has underperformed the broader market and remains in the range set last year. Heavily weighted top 10 stocks have flat revenues are are no longer growth stocks. Further u

One way to find potentially winning stocks to buy in March, April, and throughout the year is to search for companies gaining more attention from Wall Street analysts.

Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of c

Jared Ablass, Vice President, Portfolio Research at TD Asset Management, speaks with Greg Bonnell about how the biotech sector could benefit once rates start to come down. Why beaten down Biotech stoc

The 'Halftime Report' Investment Committee debates the upside potential in the biotech space.